Literature DB >> 22702446

A cross-country review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies.

Anna De Geer1, Jennifer Eriksson, Henrik W Finnern.   

Abstract

INTRODUCTION: An increased number of pharmacotherapies exist to treat advanced NSCLC. This necessitates a review of the available information on routine-care treatment patterns, the outcome of treatment, and resource utilization for patients diagnosed and treated with advanced NSCLC that could inform evidence-based treatment decisions and aid decisions on the most cost-effective treatment alternatives.
METHODS: PubMed and the Health Economic Evaluations Database were searched for retrospective or non-randomized prospective studies between January 2000 and May 2012 that included information on treatment patterns, treatment outcomes including health-related quality-of-life (HRQoL), and resource utilization. In addition, registries and databases were identified from retrieved publications and internet searches. Data collected in registries and databases was summarized for eight European countries (Belgium, France, Germany, Italy, Sweden, Turkey, the Netherlands, the UK), Australia, and Canada.
RESULTS: The literature search resulted in 410 studies, whereof 87 studies met the study inclusion criteria. In total, 49 were retrospective chart reviews or database analyses, 30 non-randomized prospective studies, and eight HRQoL studies. Two studies compared treatment patterns and/or treatment outcomes across countries. Altogether, 181 cancer registries in the countries studied were identified. Clinical cancer-specific patient registries were identified in Australia and Germany. Databases or linkage systems that enable retrieval of complete information of patient disease history were found in Australia, Canada, the Netherlands, Sweden, and the UK. Cancer registries and databases were found to collect information on NSCLC patient demographics, NSCLC or lung cancer diagnosis, disease stage, performance status, treatment, treatment outcomes, and resource use. Differences existed between country registries and databases in whether information was collected on each of these data points.
CONCLUSION: The literature review revealed few published NSCLC studies on treatment, treatment outcomes, and resource use in routine clinical practice and on HRQoL. Registries and databases were found to collect some of this information, however not systematically.

Entities:  

Mesh:

Year:  2012        PMID: 22702446     DOI: 10.3111/13696998.2012.703631

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  4 in total

1.  Cetuximab combined with chemotherapy is beneficial for patients with advanced non-small cell lung cancer after EGFR-tyrosine kinase inhibitors failure.

Authors:  Feng Zhang; You Yu; Lina Xing; Min Chen
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study.

Authors:  Dae Ho Lee; Hiroshi Isobe; Hubert Wirtz; Sabina Bandeira Aleixo; Phillip Parente; Filippo de Marinis; Min Huang; Ashwini Arunachalam; Smita Kothari; Xiting Cao; Nello Donnini; Ann-Marie Woodgate; Javier de Castro
Journal:  BMC Health Serv Res       Date:  2018-03-01       Impact factor: 2.655

3.  Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study.

Authors:  Jianping Xu; Xiaoyan Liu; Sheng Yang; Xiangru Zhang; Yuankai Shi
Journal:  Onco Targets Ther       Date:  2017-10-13       Impact factor: 4.147

4.  Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.

Authors:  Dae Ho Lee; Ming-Sound Tsao; Karl-Otto Kambartel; Hiroshi Isobe; Ming-Shyan Huang; Carlos H Barrios; Adnan Khattak; Filippo de Marinis; Smita Kothari; Ashwini Arunachalam; Xiting Cao; Thomas Burke; Amparo Valladares; Javier de Castro
Journal:  PLoS One       Date:  2018-08-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.